J. Glaspy, R. Bukowski, D. Steinberg, C. Taylor, S. Tchekmedyian and S. Vadhan-Raj, “Impact of Therapy with Epoetin Alfa on Clinical Outcomes in Patients with Nonmyeloid Malignancies during Cancer Chemotherapy in Community Oncology Practice. Procrit Study Group,” Journal of Clinical Oncology, Vol. 15, No. 3, 1997, pp. 1218-1234.

has been cited by the following article:

• TITLE: Darbepoietin-Alfa after High-Dose Melphalan and Autologous Hemopoietic Progenitor Cell in Multiple Myeloma Patients: A Pilot Study

  AUTHORS: Massimo Martino, Ida Callea, Tiziana Moscato, Antonella Pontari, Elisa Spiniello, Roberta Fedele

  KEYWORDS: Darbepoietin-Alfa; Anemia; Multiple Myeloma; Autologous Hematopoietic Progenitor Cell Transplanta-tion

  JOURNAL NAME: Open Journal of Blood Diseases, Vol.2 No.3, September 4, 2012

  ABSTRACT: We describe the effects of Darbepoietin-alfa (Darbe) administration in Multiple Myeloma (MM) after autologous he-mopoietic progenitor cell transplantation (AHPCT). 26 MM patients undergoing AHPCT entered this study. 34 hemo-globin (Hb)-matched patients who had not received recombinant human erythropoietin (Epo) or Darbe and were treated with the same protocol were retrospectively selected for comparative data. Darbe (150 micro g total dose/weekly) was initiating in four weeks after AHPCT, with the aim of achieving an Hb level of ≥11 g/dl. The time to response to Darbe therapy was longer in the patients with Hb